BioSpace News Archive

Novartis announced today that new research data from a broad range of hematology medicines and investigational therapies will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, taking place virtually December 5-8.

Novant Health, UNC Health and UNC School of Medicine have reached an agreement to expand medical education, research and clinical services to Novant Health facilities and other locations across North Carolina.

Rebus Biosystems, Inc., a life science technology company building innovative tools to enable spatial omics without compromise, today announced the closing of a $20 million Series B financing round, led by Illumina Ventures and joined by Lifecore Partners, Ncore Ventures, Xolon Invest, CTK Investments, Ray Co., Ltd.,

Invitae (NYSE: NVTA), a leading medical genetics company, today presented study findings that show nine percent of patients with pancreatic cancer had genetic changes in DNA damage repair (DDR) genes that would make them eligible for PARP inhibitor therapy or clinical treatment trials.

Biocom California, the association representing the California life science industry, announced that it has added Reza Halse, Ph.D., lead of Pacific BD&L Hub and president of Merck Research Laboratories Venture Fund;

Centinel Spine is the only company with FDA-approved cervical and lumbar total disc replacement devices

Showcased at RSNA 2020, the new fluoroscopy systems are designed to deliver rapid access to high-resolution real-time imaging of moving body structures, while reducing patient dose

IntraOp Medical Corporation and the University of Verona in Italy announced today the enrollment of the first patient in the PancFORT Trial: A phase II study of primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.

Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics, today reported third quarter 2020 financial results and operational progress.

AVROBIO, Inc., a leading clinical-stage gene therapy company, announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.